Abstract
The spate of medicolegal inquiries following the disqualification of Parlodel (bromocriptine mesylate) by the Food and Drug Administration for postpartum ablactation, uncovered previously unreported side effects associated with its postpartum administration. In 1994, bromocriptine mesylate was withdrawn from the market as a milk suppressant. Since this time, over a dozen cases of postpartum intracranial hemorrhages associated with its use have been reported. We describe three additional cases of postpartum intracranial hemorrhage related to bromocriptine usage. One patient, previously normotensive, developed hypertension and a headache; initial CT was normal, but CT 24 h later demonstrated intracranial hemorrhage. This suggests that the blood-pressure elevation was drug-induced and was the cause, rather than the consequence, of bromocriptine-related intracranial hemorrhage.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: 25 January 2000 Accepted: 7 September 2000
Rights and permissions
About this article
Cite this article
Kirsch, C., Iffy, L., Zito, G. et al. The role of hypertension in bromocriptine-related puerperal intracranial hemorrhage. Neuroradiology 43, 302–304 (2001). https://doi.org/10.1007/s002340000492
Issue Date:
DOI: https://doi.org/10.1007/s002340000492